ITA6641
ITA6641
- Catalog: ITA6641
- Gene/Protein: KIR2DL3
- Product Description: Immunotag™ KIR2DL3 Antibody
385.0000
Price in reward points: 385
Your shopping cart is empty!
Antibody Specification | |
Datasheet | |
Target Protein | KIR2DL3 |
Clonality | Polyclonal |
Storage/Stability | -20°C/1 year |
Application | WB,IHC,ELISA |
Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 |
Concentration | 1 mg/ml |
Reactive Species | Human |
Host Species | Rabbit |
Immunogen | A synthesized peptide derived from human KIR2DL3 |
Specificity | KIR2DL3 Antibody detects endogenous levels of total KIR2DL3 |
Purification | The antiserum was purified by peptide affinity chromatography. |
Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
Gene Name | KIR2DL3 |
Accession No. | P43628 |
Alternate Names | CD158 antigen like family member B2; CD158 antigen-like family member B2; CD158b; CD158b2; GL183; KI2L3_HUMAN; Killer cell immunoglobulin like receptor two domains long cytoplasmic tail 3; Killer cell immunoglobulin-like receptor 2DL3; Killer inhibitory receptor cl 2-3; Killer inhibitory receptor CL2 3; KIR 023GB; KIR-023GB; KIR-K7b; KIR-K7c; KIR023GB; KIR2DL3; KIR2DS5; KIRCL23; MHC class I NK cell receptor; Natural killer associated transcript 2; Natural killer cell inhibitory receptor KIR2DL3; Natural killer-associated transcript 2; NKAT; NKAT-2; NKAT2; NKAT2a; NKAT2b; p58; p58 natural killer cell receptor clone CL 6; p58 natural killer cell receptor clone CL-6; p58 NK Receptor; p58 NK receptor CL 6; p58 NK receptor CL-6; p58.2 MHC class I specific NK receptor; p58.2 MHC class-I-specific NK receptor; |
Description | Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis. |
Cell Pathway/ Category | Primary Polyclonal Antibody |
Protein MW | 38kDa |
Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |